Evidence map›Paper›PMID 32425110›Full record

ArticlemAbs2020

Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.

Jianlin Xu, Xuankuo Xu, Chao Huang, James Angelo, Christopher L Oliveira, Mengmeng Xu, Xia Xu, Deniz Temel, Julia Ding, Sanchayita Ghose and 2 more

Abstract readComparative Study
In one paragraph

Article in mAbs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. TiOBioprocess and biosystems engineering · 2026
    Article
  3. Review
  4. Article
  5. Development of Cell Culture Media for Cultivated Meat Production.Advances in biochemical engineering/biotechnology · 2026
    Review
  6. Review
  7. Vaccines · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jianlin XuGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0002-6441-0696
Xuankuo XuGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0002-5557-0284
Chao HuangGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0001-9355-9572
James AngeloGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0001-7939-7140
Christopher L OliveiraGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0001-9682-2292
Mengmeng XuGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Xia XuGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Deniz TemelGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Julia DingGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Sanchayita GhoseGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Michael C BorysGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.
Zheng Jian LiGlobal Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.ORCID 0000-0002-1941-4145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8) and 2000-L scales (Process C, n = 3) for the production of a monoclonal antibody by a Chinese hamster ovary cell line. For the upstream part of the process, we implemented an intensified seed culture scheme to enhance cell densities at the seed culture step (N-1) prior to the production bioreactor (N) by using either enriched N-1 seed culture medium for Process B or by operating the N-1 step in perfusion mode for Process C. The increased final cell densities at the N-1 step allowed for much higher inoculation densities in the production bioreactor operated in fed-batch mode and substantially increased titers by 4-fold from Process A to B and 8-fold from Process A to C, while maintaining comparable final product quality. Multiple changes were made to intensify the downstream process to accommodate the increased titers. New high-capacity resins were implemented for the Protein A and anion exchange chromatography (AEX) steps, and the cation exchange chromatography (CEX) step was changed from bind-elute to flow-through mode for the streamlined Process B. Multi-column chromatography was developed for Protein A capture, and an integrated AEX-CEX pool-less polishing steps allowed semi-continuous Process C with increased productivity as well as reductions in resin requirements, buffer consumption, and processing times. A cost-of-goods analysis on consumables showed 6.7-10.1 fold cost reduction from the conventional Process A to the intensified Process C. The hybrid-intensified process described here is easy to implement in manufacturing and lays a good foundation to develop a fully continuous manufacturing with even higher productivity in the future.

Indexed as

AnimalsAntibodies, MonoclonalBioreactorsBiotechnologyCell Culture TechniquesCell ProliferationCHO CellsCosts and Cost AnalysisCricetinaeCricetulusEfficiencyHumansInventionsModels, EconomicAntibodies, Monoclonalbiomanufacturingcost of goodsintegrated pool-less polishingmonoclonal antibodymulti-column chromatographyN-1 perfusionProcess intensificationquality

Identifiers

PMID32425110
PMCPMC7531520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.